Gapping up
In reaction to strong earnings/guidance:
- MKC +4.4%
M&A news:
- TOO +32.8% (to be acquired by Brookfield (BBU) for $1.55/unit in cash)
Select financial related names showing strength:
- BBVA +1.2%, BK +1%, MS +1%, JPM +0.8%, C +0.8%, GS +0.6%
Other news:
- GERN +13.5% (announces Fast Track designation granted to imetelstat for relapsed/refractory myelofibrosis)
- BKD +3.6% (announces multi-part transaction with HCP)
- WPP +1% (new CFO)
- STML +0.9% (presents updated clinical data on felezonexor (SL-801) Phase 1 trial in patients with advanced solid tumors)
Analyst comments:
- ACAD +4.7% (initiated with an Outperform at RBC Capital Mkts)
- EYE +3.6% (upgraded to Buy from Neutral at BofA/Merrill)
- ADI +2.9% (upgraded to Overweight from Sector Weight at KeyBanc Capital Markets)
- VMW +2.6% (upgraded to Outperform from Market Perform at Wells Fargo)
- TW +2.1% (upgraded to Overweight from Equal Weight at Barclays)
- MCHP +1.6% (upgraded to Overweight from Sector Weight at KeyBanc Capital Markets), PM +1.4% (upgraded to Buy from Neutral at BofA/Merrill)
- BX +1.4% (initiated with an Outperform at Wells Fargo)
- IOVA +1.1% (initiated with a Buy at Stifel)
- SMG +0.8% (upgraded to Neutral from Underperform at BofA/Merrill)